

**CLINICAL SIGNIFICANCE OF PLASMA THROMBOMODULIN
LEVEL IN DIABETES MELLITUS**

Thesis

Submitted for The Fulfillment

Of

Master Degree in Internal Medicine

616.462
S. A

By

Salah Eldin Ahmed Nasr
M.B., B. Ch.

Supervisors

Dr: Enas. A. Assfour
Professor of Internal Medicine
Ain Shams University

Dr. Noura M. Elkholy
Assistant Professor of Biochemistry
Ain Sham University

Dr. Hanan Hamed
Lecturer of Internal Medicine
Ain Shams University

Department of Internal Medicine
Faculty of Medicine, Ain Shams University

1997



53873



د. هاني هادي
د. نورا م. Elkholy
د. Enas. A. Assfour

٢٤

٢٤








To..... My Mother



CONTENTS

Introduction	1
Aim of the work	3
Review of literature	4
• Diabetes mellitus	4
• Endothelium	21
• Thrombomodulin	26
Subjects and methods	48
Results	69
Discussion	80
Summary and conclusions	90
References	92





INTRODUCTION



INTRODUCTION

Thrombomodulin (TM) is a surface glycoprotein which neutralizes thrombin clotting and platelet aggregatory activity and acts as a cofactor for thrombin catalyzed activation of anticoagulant protein C.

Circulating thrombomodulin is not constantly secreted by endothelial cells but results from cellular damage. Unlike von Willebrand factor and tissue plasminogen activator, circulating TM is not a marker of endothelial cell stimulation, and the endothelial membrane TM is hardly leaked in absence of endothelial injury. The liver is considered the major site of clearance of circulating TM, and patients with liver disease especially fulminant hepatitis were reported to have elevated plasma TM levels (Takahashi et al., 1992). In addition the change in urinary excretion of TM may modify its plasma (Ishii and Majerus, 1985).

Plasma TM has been frequently reported to be elevated in a variety of diseases including DIC, pulmonary thromboembolism, acute respiratory distress, chronic renal failure, collagen diseases, hematological malignancies, as well as in thrombotic diseases. These

findings suggest that the endothelial damage may occur more frequently than hitherto supposed (**Ta Kahashi et al., 1992**).

Subclinical elevation of urinary albumin, microalbuminurea, is well described as being a predictor for cardiovascular disease in both diabetic and nondiabetic subjects. It reflects the presence of generalized vascular damage and represents a crucial event in the natural histories of diabetes mellitus and essential hypertension (**Yudkin et al., 1988**). An increased risk of cardiovascular mortality in both insulin - dependent (IDD) and noninsulin-dependent (NIDD) diabetics has been recorded in association with microalbuminurea and the risk becomes 20 - to 40 fold higher with development of clinical proteinuria, macroalbuminurea in IDD (**Borch et al., 1985**).



AIM OF THE WORK



